Gastroenterologische Gemeinschaftspraxis Minden

Publikationen

Langbrandtner J, Huppe A, Jessen P, Buning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017; 10: 215-27 Link

Hartmann P, Bokemeyer B. Anti-TNF-α--Wirkstoffe bei chronisch entzündlichen Darmerkrankungen (2017). Pharmakon 2017;5:356-364 Link

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease(2017). Dig Liver Dis. 2017 Aug 1. pii: S1590-8658(17)30985-4. doi: 10.1016/j.dld.2017.07.010 Link

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Siegmund B, Schmidt C, Stallmach A, German IBD Study group. Azathioprine allows glucocorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases (2017). Z Gastroenterol. 2017;55:461-465. doi: 10.1055/s-0043-106310. Link

Bokemeyer B, Dignaß A, Schreiber S. Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists (2017). Z Gastroenterol. 2017;55(4):369-374. Link

Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A; German IBD Study Group. Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD (2017). Gut. 2017;66(8):1531-1532. Link

Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study (2017). Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. Link

Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mroß M, Mallard N. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency (2017). Eur J Drug Metab Pharmacokinet. 2017;42(2):229-238. Link

Stallmach A, Bokemeyer B, Axler J, Curtis R, Ehehalt R, Feagan B, Geransar P, James A, Kaviya A, Khalid J.M, Wolf D, Schreiber S. DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters (2017). Journal of Crohn s and Colitis 11;S42-S43. Link

Kruis W, Leifeld L, Hoepffner N, Hoesl M, Jessen P, Mross M, Klugmann T, Ceplis-Kastner S, Reimers B, Bokemeyer B. A Prospective Study to Predict a Mild Course of Crohn's Disease: An Interim Analysis of the Prognos-Study (2017). Gastroenterol. 2017;152;377. Link

Siegel, CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Luous E, Sebastian S, Hebuterne X, Bell A, Södermann C, Schuber S, Atreya R, Polyak S, Hoque S, Krummenerl A, Bokemeyer B, Krummenerl T, Shulmann S, Karlén P, Moum B, Dolin P. P501 Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) 2017. J Crohns Colitis; 11: S333-S334. Link

Bokemeyer B, Schreiber S. Versorgungsfokus. CED chronisch-entzündliche Darmerkrankungen. Arbeitsgemeinschaft Pro Biosimilars. 2016. probiosimilars.de/publikationen/versorgungsfokus-ced. Link

Schreiber S, Hartmann H, Kruis W, Kucharzik T, Mudter J, Siegmund B, Stallmach A, Witte C, Fitzke K, Bokemeyer B. Inflammatory Bowel Disease Competence Network (2016). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 201;59(4):465-74. Link

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity (2016). J Crohns Colitis. 2016 Jan;10(1):61-8. Link

Siegmund B, Atreya R, Bokemeyer B, Kruis W, Mudter J, Sander C, Schreiber S, Reindl W, Zeissig S, Kucharzik T. Biosimilars in inflammatory bowel disease (2016). Z Gastroenterol. 2016;54;1217-1222. Link

Sternkopf J, Bokemeyer B, Tappe U, Schultz C. Potenziale einer integrierten Versorgung (2016). Deutsches Ärzteblatt 113;46;A2090-2092 Link

Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen GC, Bokemeyer B, Lindsay J, Smyth M, Munsaka M, Ramagopalan S, Khalid JM. OP008. Predictors of NON-Response or loss of response to tumour necrosis factor antagonist therapies in inflammatory bowel disease (2016). United European Gastroenterology Journal 4 Supplement 1;4. Link

Diese Webseite verwendet Cookies. Mehr zum Datenschutz